About Synklino
Synklino is a company based in Copenhagen (Denmark) founded in 2017 by Mads Gravers Jeppesen and Thomas Nitschke Kledal. Synklino has raised $32.25 million across 5 funding rounds from investors including PKA, Eir Ventures and Danmarks Eksport- og Investeringsfond. The company has 8 employees as of November 30, 2024. Synklino offers products and services including SYN002. Synklino operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, CareDx, Generate Biomedicines and HOOKIPA Pharma, among others.
- Headquarter Copenhagen, Denmark
- Employees 8 as on 30 Nov, 2024
- Founders Mads Gravers Jeppesen, Thomas Nitschke Kledal
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Synklino Aps
-
Annual Revenue
Not available
-
Net Profit
-$1.52 K (USD)80as on Dec 31, 2022
-
EBITDA
Not available
-
Total Equity Funding
$32.25 M (USD)
in 5 rounds
-
Latest Funding Round
$31.9 M (USD), Series A
Jun 08, 2022
-
Investors
PKA
& 2 more
-
Employee Count
8
as on Nov 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Synklino
Synklino offers a comprehensive portfolio of products and services, including SYN002.
Eliminates CMV risk in transplant recipients via ex vivo or in vivo treatment.
People of Synklino
Unlock access to complete
Unlock access to complete
Funding Insights of Synklino
Synklino has successfully raised a total of $32.25M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $31.9 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Synklino
Synklino has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include PKA, Eir Ventures and Danmarks Eksport- og Investeringsfond.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is provided for innovative medical developments.
|
Locked | Locked | Locked | |
|
Provision of financing, loans, equity, and insurance for Danish export and investment activities.
|
Locked | Locked | Locked | |
|
Serves as a pension fund providing benefits for employees.
|
Locked | Locked | Locked |
Investor details for Synklino
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Synklino
Investment portfolio details for Synklino
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Synklino
Detailed financials for Synklino
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Synklino Comparisons
Peer comparison for Synklino
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Synklino
Synklino operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, CareDx, Generate Biomedicines and HOOKIPA Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Medical solutions for transplant patients are developed and provided.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Developer of biologics to treat hepatitis B infection
|
Detailed competitors of Synklino
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Synklino
Complete news archive for Synklino
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synklino
Synklino was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Synklino is headquartered in Copenhagen, Denmark.
Thomas Nitschke Kledal is the current CEO of Synklino. They have also founded this company.
Synklino is a funded company, having raised a total of $32.25M across 5 funding rounds to date.
As of Nov 30, 2024, the latest employee count at Synklino is 8.
Synklino was founded in 2017 in Copenhagen, Denmark, within the biotechnology sector. Focus is placed on developing therapeutic drugs for chronic viral infections. The lead product candidate, SYN002, is an immunotoxin designed to target the US28 receptor for Cytomegalovirus (CMV) treatment. Operations center on advancing these antiviral therapies through research and clinical development stages. Co-founders include Mads Gravers Jeppesen and Thomas Nitschke Kledal, with the latter serving as CEO.
Synklino's top competitors include Moderna, CareDx and Adaptive Biotechnologies.
Synklino offers SYN002.
Synklino has 3 investors. Key investors include PKA, Eir Ventures, and Danmarks Eksport- og Investeringsfond.
The valuation of Synklino is $4.4M as of Nov 2021.